Rigel Pharmaceuticals
RIGLApprovedRigel Pharmaceuticals is a commercial-stage biotech with a strategic focus on hematology and oncology, building a portfolio of approved and investigational therapies. The company has successfully brought multiple products to market, including TAVALISSE for ITP and REZLIDHIA for AML, and is advancing a pipeline through both internal R&D and strategic collaborations, such as its partnership with Eli Lilly on a RIPK1 inhibitor. Headquartered in South San Francisco, Rigel operates as a public company (NASDAQ: RIGL) and is led by a seasoned management team with deep experience in biopharma development and commercialization.
RIGL · Stock Price
Historical price data
AI Company Overview
Rigel Pharmaceuticals is a commercial-stage biotech with a strategic focus on hematology and oncology, building a portfolio of approved and investigational therapies. The company has successfully brought multiple products to market, including TAVALISSE for ITP and REZLIDHIA for AML, and is advancing a pipeline through both internal R&D and strategic collaborations, such as its partnership with Eli Lilly on a RIPK1 inhibitor. Headquartered in South San Francisco, Rigel operates as a public company (NASDAQ: RIGL) and is led by a seasoned management team with deep experience in biopharma development and commercialization.
Technology Platform
Small molecule drug discovery focused on intracellular signaling pathways, particularly kinases and enzymes involved in hematologic disorders, cancer, and immune dysregulation.
Pipeline Snapshot
3838 drugs in pipeline, 6 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Prob... | AML (Acute Myeloid Leukemia) | Approved |
| Fostamatinib disodium + Placebo | Warm Antibody Autoimmune Hemolytic Anemia | Phase 3 |
| Fostamatinib disodium + Placebo | Immune Thrombocytopenic Purpura | Phase 3 |
| Fostamatinib disodium | Warm Antibody Autoimmune Hemolytic Anemia | Phase 3 |
| Fostamatinib Disodium | Immune Thrombocytopenic Purpura | Phase 3 |
Funding History
2Total raised: $92M
FDA Approved Drugs
3Opportunities
Risk Factors
Competitive Landscape
Rigel competes with larger pharmaceutical companies in ITP (e.g., Amgen with Nplate, Novartis with Promacta) and AML (e.g., Servier with Tibsovo). Its differentiation lies in its focused hematology/oncology expertise, targeted mechanisms of action (SYK, IDH1 inhibition), and oral small molecule formulations. In pipeline areas like MDS and immunology, it faces competition from both biotech and pharma entities developing novel pathway inhibitors.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile